Goldman Sachs
ELDN icon

Goldman Sachs’s Eledon Pharmaceuticals ELDN Stock Holding History

Goldman Sachs’s Portfolio ELDN Stock Details ELDN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$1.14M Buy
370,090
+171,378
+86% +$404K ﹤0.01% 5007
2025
Q4 		$300K Buy
198,712
+137,706
+226% +$327K ﹤0.01% 5866
2025
Q3 		$158K Buy
61,006
+34,135
+127% +$99.8K ﹤0.01% 6000
2025
Q2 		$72.8K Sell
26,871
-231,235
-90% -$694K ﹤0.01% 5873
2025
Q1 		$875K Buy
258,106
+113,261
+78% +$466K ﹤0.01% 4796
2024
Q4 		$597K Buy
+144,845
New +$571K ﹤0.01% 5141
2017
Q3 		– Sell
-719
Closed -$76K – 6698
2017
Q2 		$76K Buy
719
+622
+641% +$63.4K ﹤0.01% 6225
2017
Q1 		$13K Sell
97
-288
-75% -$42.3K ﹤0.01% 6582
2016
Q4 		$61K Buy
385
+253
+192% +$48.5K ﹤0.01% 6332
2016
Q3 		$33K Sell
132
-28
-18% -$10.2K ﹤0.01% 6612
2016
Q2 		$143K Buy
160
+40
+33% +$44.1K ﹤0.01% 5928
2016
Q1 		$109K Buy
120
+17
+17% +$16.7K ﹤0.01% 6034
2015
Q4 		$146K Buy
103
+27
+36% +$47K ﹤0.01% 5928
2015
Q3 		$128K Buy
76
+1
+1% +$2.06K ﹤0.01% 6318
2015
Q2 		$162K Sell
75
-17
-18% -$32.9K ﹤0.01% 6307
2015
Q1 		$169K Sell
92
-130
-59% -$287K ﹤0.01% 6130
2014
Q4 		$530K Buy
+222
New +$527K ﹤0.01% 5228

Other funds holding ELDN

BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
DCM
Defilade Capital Management Emeryville, California $712M AUM
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Ensign Peak Advisors
Ensign Peak Advisors Salt Lake City, Utah $53.7B AUM 29.47% 1-Year Est. Return
ZP
Zimmer Partners New York $4.15B AUM 14.2% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
SFM
Sphera Funds Management Tel Aviv, Israel $630M AUM 108.65% 1-Year Est. Return
CCM
Catalio Capital Management New York $479M AUM 140.7% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Goldman Sachs's ELDN Position: Q1 2026 in Review

Goldman Sachs increased its Eledon Pharmaceuticals (ELDN) stake by 86% in Q1 2026, buying an estimated $404K and bringing the position to 370,090 shares worth $1.14M. The position accounts for ﹤0.01% of the portfolio, ranked #5007.

Goldman Sachs first reported a position in ELDN in Q4 2014 and has held it in 17 quarters since. 121 funds tracked by Wall St. Rank hold ELDN as of Q1 2026.

  • Goldman Sachs held 370,090 shares of Eledon Pharmaceuticals worth $1.14M as of Q1 2026.
  • Goldman Sachs bought 171,378 Eledon Pharmaceuticals shares in Q1 2026, an estimated $404K.
  • Eledon Pharmaceuticals made up ﹤0.01% of Goldman Sachs's portfolio in Q1 2026, its #5007 holding.
  • Goldman Sachs first reported a position in Eledon Pharmaceuticals in Q4 2014 and has held it in 17 quarters since.
  • 121 funds tracked by Wall St. Rank held Eledon Pharmaceuticals as of Q1 2026.

Based on Goldman Sachs's 13F filing for Q1 2026, filed 15 May 2026.